Yishai Levin

Lab head

Weizmann Institute of Science
Country flagIsrael
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (2)

New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo . Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.

Year:

2026

Bone-resorbing osteoclasts (OCLs) are large, multi-nucleated cells that are formed through well-regulated differentiation and cell fusion of monocyte-macrophage precursors. Abnormally increased or decreased OCL-mediated bone resorption perturbs bone structure and homeostasis and may lead to severe illnesses, such as osteoporosis and autosomal recessive osteopetrosis (ARO), respectively. Mutations in the intracellular trafficking-associated protein sorting nexin 10 (SNX10) lead to “OCL-rich” ARO, in which OCLs are inactive. Mature, SNX10-deficient murine OCLs fuse continuously to generate gigantic cells, in vitro and in vivo, unlike WT OCLs that stop fusing with each other upon maturation, indicating that SNX10 is required for both the resorptive activity of OCLs and the arrest of cell fusion upon maturation. Mutations in CLC-7 and OSTM1, which comprise the lysosomal voltage-gated Cl−/H+ exchanger, also induce OCL-rich ARO in humans and in mouse models, and are associated with the presence of large OCLs. In this study, we explored the molecular interplay between SNX10, CLC-7, and OSTM1 by comparing the phenotypes of cultured mouse OCLs lacking one of these proteins. We show that loss of each protein leads to the formation of similarly-gigantic OCLs in culture, due to deregulated fusion between mature OCLs that proceeds with similar kinetics. All 3 proteins co-localize in LAMP1-positive lysosomes, located at both perinuclear and peripheral regions of mature WT OCLs. SNX10-KO OCLs exhibit few peripheral lysosomes containing CLC-7 and OSTM1, indicating that SNX10 is required for regulating their trafficking to the cell periphery. CLC-7 and SNX10 physically interact with each other and loss of CLC-7 depletes peripheral OSTM1-containing lysosomes, indicating that CLC-7 is also required for this transport. Taken together, these findings indicate that SNX10 and CLC-7 regulate the subcellular distribution of lysosomes containing CLC-7 and OSTM1, thereby establishing a functional link between these 3 proteins that controls both the fusion and functionality of mature OCLs.

Year:

2025

Collaborators (12)

Roni Oren

Head of Patient Derived Xenograft (PDX) Service and Human Tissue Samples Bank

Weizmann Institute of Science

ISRAEL
View details

Olga Troyanskaya

Professor

Princeton University

UNITED STATES
View details

Francisco Martínez-Jiménez

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Shifra Ben-Dor

Senior Staff Scientist

Weizmann Institute of Science

ISRAEL
View details

Niroshana Anandasabapathy

Associate Professor of Dermatology

Weill Cornell Medical College

UNITED STATES
View details

Abel Gonzalez-Perez

Co-PI

IRB Barcelona

SPAIN
View details

Joaquin Mateo

Group Leader

Vall d´Hebron Institute of Oncology

SPAIN
View details

Ari Elson

Professor

Weizmann Institute of Science

ISRAEL
View details

Nuria Lopez-Bigas

ICREA Research Professor-Group Leader

Universitat Pompeu Fabra

SPAIN
View details